Table 2. Diagnostic performance of miRNA panels in combination with alpha-fetoprotein in differentiating HCC against control subjects.
| Variable(s) | Area Under the Curve (AUC) | |||
|---|---|---|---|---|
| HCC vs. LC | HCC vs. CHB | HCC vs. (CHB+LC) | HCC vs. (CHB+LC+HC) | |
| miR-21 | 0.698 (P<0.05) | 0.805 (P<0.05) | 0.757 (P<0.05) | 0.810 (P<0.05) |
| miR-122 | 0.775 (P<0.05) | 0.922 (P<0.05) | 0.862 (P<0.05) | 0.908 (P<0.05) |
| miR-192 | 0.664 (P<0.05) | 0.895 (P<0.05) | 0.806 (P<0.05) | 0.872 (P<0.05) |
| AFP | 0.733 (P<0.05) | 0.765 (P<0.05) | 0.753 (P<0.05) | Not applicable |
| miR21+miR122+miR192 (a) | 0.774 (P<0.05) | 0.906 (P<0.05) | 0.810 (P<0.05) | 0.854 (P<0.05) |
| miR21+miR122+miR192 (b) | 0.744 (P<0.05) | 0.922 (P<0.05) | 0.836 (P<0.05) | 0.862 (P<0.05) |
| miR21+miR122+miR192+AFP (a) | 0.887 (P<0.05) | 0.948 (P<0.05) | 0.887 (P<0.05) | Not applicable |
| miR21+miR122+miR192+AFP (b) | 0.734 (P<0.05) | 0.925 (P<0.05) | 0.850 (P<0.05) | Not applicable |
| miR-21 (c) | 0.714 (P<0.05) | 0.798 (P<0.05) | 0.764 (P<0.05) | 0.811 (P<0.05) |
| miR-122 (c) | 0.799 (P<0.05) | 0.933 (P<0.05) | 0.878 (P<0.05) | 0.920 (P<0.05) |
| miR-192 (c) | 0.692 (P<0.05) | 0.922 (P<0.05) | 0.828 (P<0.05) | 0.888 (P<0.05) |
| AFP (c) | 0.742 (P<0.05) | 0.772 (P<0.05) | 0.760 (P<0.05) | Not applicable |
| miR21+miR122+miR192 (c) | 0.805 (P<0.05) | 0.912 (P<0.05) | 0.849 (P<0.05) | 0.883 (P<0.05) |
| miR21+miR122+miR192+AFP (c) | 0.913 (P<0.05) | 0.967 (P<0.05) | 0.920 (P<0.05) | Not applicable |
CHB: chronic hepatitis B; LC: HBV-related liver cirrhosis; HCC: HBV-related hepatocellular carcinoma; AFP: alpha-fetoprotein;
(a): Diagnostic performance of miRNA panel and in combination with AFP levels in all study subjects;
(b): Diagnostic performance of miRNA panel when patients were stratified according to AFP level lower than 20 ng/l.
(c): Diagnostic performance of each miRNA, the miRNA panel and the miRNA panel in combination with AFP levels in differentiating HCC with small tumor size (<5 cm) from other groups.